29th Mar 2010 12:27
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: |
BIOFUTURES INTERNATIONAL PLC |
2 Reason for the notification (please tick the appropriate box or boxes): |
||
An acquisition or disposal of voting rights |
ü |
|
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|
An event changing the breakdown of voting rights |
|
|
Other (please specify): |
|
|
3. Full name of person(s) subject to the notification obligation:
|
Gartmore Investment Limited |
4. Full name of shareholder(s) (if different from 3.):
|
See attached Schedule |
5. Date of the transaction and date on which the threshold is crossed or reached:
|
22 March 2010 |
6. Date on which issuer notified:
|
23 March 2010 |
7. Threshold(s) that is/are crossed or reached:
|
10% |
8. Notified details: |
|||||||
A: Voting rights attached to shares
|
|||||||
Class/type of shares if possible using the ISIN CODE |
Situation previous to the triggering transaction |
Resulting situation after the triggering transaction |
|||||
Number of Shares |
Number of Voting Rights |
Number of shares |
Number of voting rights |
% of voting rights |
|||
Direct |
Direct |
Indirect |
Direct |
Indirect |
|||
ORDINARY GB00B12B4T47
|
10,975,000 |
10,975,000 |
15,934,030 |
- |
15,934,030 |
- |
10.548% |
B: Qualifying Financial Instruments |
||||
Resulting situation after the triggering transaction
|
||||
Type of financial instrument |
Expiration date |
Exercise/ Conversion Period |
Number of voting rights that may be acquired if the instrument is exercised/ converted.
|
% of voting rights |
|
|
|
|
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||
Resulting situation after the triggering transaction
|
||||||
Type of financial instrument |
Exercise price |
Expiration date |
Exercise/ Conversion period |
Number of voting rights instrument refers to |
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
Total (A+B+C)
|
|
Number of voting rights |
Percentage of voting rights |
15,934,030 |
10.548% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: |
|
Proxy Voting:
|
|
10. Name of the proxy holder:
|
|
11. Number of voting rights proxy holder will cease to hold:
|
|
12. Date on which proxy holder will cease to hold voting rights:
|
|
13. Additional information:
|
All figures are based on the Company's issued share capital of 151,060,000 as provided by Exshare
E-mail contact: [email protected]
|
14. Contact name:
|
RDU |
15. Contact telephone number:
|
0207 782 2324 |
For further information contact: |
JULIE POMEROY, FINANCE DIRECTOR, BIOFUTURES INTERNATIONAL PLC - 07747 624 199
DEREK CROWHURST, RELIGARE CAPITAL MARKETS (NOMAD) - 0207 444 0800
DANIEL BRIGGS, RELIGARE CAPITAL MARKETS (BROKER) - 0207 444 0500 |
Schedule
Fund Managing Company |
UK Registered Owner |
Beneficial Owner |
% of Issued Share Capital |
Shares Held |
Gartmore Fund Managers Limited |
HSBC Global Custody Nominee UK Ltd |
Gartmore Fund Managers Ltd A/C Gartmore UK & Irish Smaller Companies |
4,375,000 |
2.896% |
Gartmore Investment Limited |
Nortrust Nominees Limited |
Strathclyde Pension Fund |
4,550,000 |
3.012% |
Gartmore Growth Opportunities |
Gartmore Growth Opportunities Plc |
1,034,030 |
0.685% |
|
Vidacos Nominees Ltd A/C 2303 |
The Alphagen Volantis Fund Limited |
5,975,000 |
3.955% |
|
Total |
15,934,030 |
10.548% |
Related Shares:
Graphene Nanochem